Alnylam Pharmaceuticals Community

NasdaqGS:ALNY Community

2 Narratives written by author
0 Comments on narratives written by author
20 Fair Values set on narratives written by author

Alnylam Pharmaceuticals

AN

AnalystHighTarget

Consensus Narrative from 31 Analysts

Vutrisiran Approval And Nucresiran Pipeline Will Unlock New Markets

Key Takeaways Approval of vutrisiran could expand Alnylam's franchise, driving significant revenue growth by capturing a larger patient population. Strategic commercial plans and RNAi therapeutic developments may boost long-term growth, with stable revenue from expanded access and value-based agreements.

US$371.81

FV

35.4% undervalued

61.14%

Revenue growth p.a.

0

0

0

1 day ago

Alnylam Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 31 Analysts

Vutrisiran And AMVUTTRA Approvals Will Transform The TTR Franchise

Key Takeaways Vutrisiran's approval and AMVUTTRA's anticipated approval in ATTR cardiomyopathy are expected to drive significant revenue and profit growth for Alnylam. New product launches and partnerships with industry leaders position Alnylam for sustainable innovation and increased financial resilience.

US$314.48

FV

23.7% undervalued

28.94%

Revenue growth p.a.

1

0

12

6 days ago